STOCKS TELEGRAPH

Author: Maria Masood

  • Here’s What you Should Know About Leaping Premarket Pixelworks, Inc. (PXLW) Stock.

    Pixelworks, Inc. (PXLW) is a leading content creator in the industry. It also provides display processing and video delivery solutions and superior visual quality content. The company provides its services across all screen formats.

    The price of PXLW stock during the regular trading on February 1, 2022, was $3.44 with a 2.69% surge. At last check in the premarket on February 2, 2022, the stock further went up by 7.56%.

    PXLW: Events and Happenings

    On January 31, 2022, PXLW’s CFO acquired 2794 shares of the company’s stock at a price of $2.56 per share. The total value of the shares was $7148. On January 26, 2022, PXLW updated about releasing its Q4 and full fiscal year 2021 financial results on February 10, 2022. The company announced its preliminary Q4 financials on Jan. 11, 2022, as the quarter ended December 31, 2021. The analysts expected EPS (loss) for the company to be approximately $0.05 and the revenue is estimated to be $16.47 million.

    On January 11, 2022, PXLW and OnePlus co-announced the incorporation of the company’s innovative Pro Software solution in OnePlus’ 10 Pro smartphone. The new feature brings reliable color precision and eye comfort. On January 10, 2022, PXLW updated about management participation at the Virtual 24th Annual Needham Growth Conference on January 12, 2022.

    On January 5, 2022, PXLW reported about the incorporation of its X5 Pro visual processor in iQOO 9 series smartphones. This feature helps reinforce the capability of players in the game. On December 16, 2021, PXLW updated about launching TrueCut Motion which is the pioneer motion-imaging end-to-end portfolio. It offers cutting-edge proficiency tools to control motion visualization in films is visualized in their films along with many other facilities.

    On December 16, 2021, PXLW and MediaTek entered into an agreement for the accessibility of visual display processing for mobile products. On December 15, 2021, PXLW and OPPO co-reported the incorporation of the company’s color and brightness calibration expertise to the OPPO Find N smartphone.

    PXLW: Key Financials

    On November 9, 2021, PXLW released its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Revenue in Q3 2021 was $15.2 million, compared to $8.2 million in the same period of 2020. PXLW beats on the revenue by $343.7 thousand.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $4.1 million or $0.08 against $4.4 million or $0.08 in same quarter of 2020. The company’s EPS beat by $0.01 as reported by analysts.

    Conclusion

    PXLW’s stock is performing sound in the recent few months as it gained 16%. The recent activity in the premarket is the result of an insider transaction of the shares by the company’s CFO. The current market position of the company is good for the investors as observed by the analysts.

  • Epizyme, Inc. (EPZM) Stock Growing in Pre-Market, Here’s the Reason

    Epizyme, Inc. (EPZM) is a biotherapeutics company engaged in the commercialization of therapeutics for oncological disorders using novel epigenetic treatments. The pipeline candidates of the company include Tazemetostat for curing follicular lymphoma, R-CHOP for DLBCL, and PARP for solid tumors.

    The price of EPZM stock during the regular trading on February 1, 2022, was $1.23. At last check in the pre-market, the stock gained by 8.94%.

    EPZM: Events and Happenings

    On February 1, 2022, EPZM’s employee bought 22,666,667 shares of the company’s stock at a price of $1.5 per share. On January 27, 2022, EPZM reported about the public pricing of its common stock shares of 56,666,667 shares at $1.50 per share price. The company had also granted the underwriters the acquisition of additional 8,500,000 common stock shares. The net proceeds expected by the company from the offering are approximately $85.0 million.

    On January 10, 2022, EPZM updated about the preliminary results of the fourth quarter of 2021. The company estimated the revenue to be approximately $20.4 million while the earnings per share are estimated to beat by $0.52.

    On December 12, 2021, EPZM’s Executive management presented the data of TAZVERIK at the 63rd American Society of Hematology’s Annual Meeting. On December 11, 2021, the company’s management presented the data of EZM0414 at the 63rd Annual Meeting of the American Society of Hematology.

    On November 12, 2021, EPZM updated about the participation of its Executives at the Jefferies London Healthcare Conference on November 18, 2021.

    EPZM: Key Financials

    On November 9, 2021, EPZM announced its third-quarter 2021 financial results. The quarter ended on September 30, 2021. Some of the key updates are as follows.

    Revenue

    Total revenue in Q3 2021 was $5.2 million, compared to $3.6 million in Q3 2020. The company missed the revenue by $3.45 million.

    Earnings/Loss per Share

    EPS in Q3 2021 were $65.8 million, or $0.64 per share compared to $56.1 million or $0.55 per share in the same quarter of 2020. The company beat the EPS by $0.20 during the quarter.

    Conclusion

    EPZM stock’s performance is on a downward spiral by 81% from the past few months period. The stock looked well-positioned in the recent pre-market after the current insider transaction of shares by its employee. The financial experts have a strong consensus about the company’s earnings improvement.

  • Great Panther Mining Ltd. (GPL) Stock Up in the Aftermarket, Here’s What you Should Know.

    Great Panther Mining Ltd. (GPL) is a mineral exploration firm focusing primarily on silver, gold, copper, lead, and zinc ores. It possesses a wide collection of assets in different regions. The company creates long-term and investor-based value via safe and sustainable manufacturing.

    The price of GPL stock during the regular trading on February 1, 2022, was $0.15 with a significant 20.8% fall. At last check in the aftermarket, the stock gained momentum by 26.2%.

    GPL: Events and Happenings

    GPL announced its production outcomes on January 19, 2022, for the three months ended December 31, 2021. The company is also planning to release Q4 results on March 2, 2022. Some of the key production updates are as follows.

    • Combined metal production of 24,284 gold equivalent ounces, including 20,850 gold ounces and 227,084 silver ounces.
    • Cumulative gold production at Tucano mine of 19,330 gold ounces.
    • Cumulative silver equivalent production at Topia mine of 212,006 silver equivalent ounces.
    • Cumulative silver equivalent production at the GMC mine of 209,074 silver equivalent ounces.

    Great Panther Mining Ltd. (GPL) reported the closure of its underwritten public offering of 88,461,538 ordinary shares of the company in its capital on November 12, 2021. Additionally, the underwriters were given the option of acquisition of supplementary 11,538,461 shares. The public offering price of the shares was $0.26 per share for the combined net proceeds of almost $23 million.

    GPL: Key Financials

    GPL updated on November 3, 2021, about its financial outcomes for the three months ended September 30, 2021. Some of the key points are as follows.

    Revenue

    Revenue of $38.4 million was recorded in Q3 2021, versus $77 million in the same period of 2020. The company’s revenue declined by 50% over the year.

    Net Income/Loss

    Basic and diluted net loss per share in Q3 2021 was $18.0 million or $0.05 compared to the net income of $18.6 million or $0.05 in Q3 2020.

    Great Panther Mining Ltd. (GPL) updated on October 18, 2021, about its geotechnical committee had recommended supplementary remediation effort on one of its ore’s open pit to reduce safety concerns. The mining process had been suspended briefly to take safety measures for the wellbeing of employees.

    Conclusion

    The past few months have negatively impacted businesses due to the global pandemic. Almost all the major companies’ stock dip in the period. GPL stock also down performed by 73% from the past few months. The company’s stock gained notably in the current aftermarket session as a result of uncertain factors and there is no recent company news available.

  • Creative Realities, Inc. (CREX) Stock Rocketing Higher in Early Trading. Here’s why.

    Creative Realities, Inc. (CREX) Stock Rocketing Higher in Early Trading. Here’s why.

    Creative Realities, Inc. (CREX) is engaged in designing, developing, and deployment of customer experience for enterprise-level platforms. The company is the provider of SaaS across markets including automotive, apparel, food service, theater, and many others.

    The price of CREX stock during the early trading on February 1, 2022, was last checked to be $1.68 with a 17.40% incline.

    CREX: Events and Happenings

    On February 1, 2022, CREX and Reflect Systems, Inc. co-reported their major plan for the deployment of digital experience at multiple localities. The total value of the project is approximately $10 million.

    CREX: CEO Comments

    Speaking at the occasion, CREX CEO Rick Mills stated that the merger project will serve as the basis of the strongest platform in the industry. He further added that this announcement has sent the company’s consumers a new and exciting portfolio that they want to consider.

    On November 17, 2021, CREX reported about the expansion of its partnership with a leading international automotive production Canadian company. The company had been granted additional 440 dealerships by the Canadian giant company. The deployment will complete in Q2 2022.

    On November 12, 2021, CREX reported along with Reflect Systems, Inc. about their definitive combination contract. The merger operated under the name and ticker of Creative Realities.

    CREX: Key Financials

    On November 15, 2021, CREX announced its financial results for the three months ended September 30, 2021. Some of the key points are as follows.

    Revenue and Assets

    Total revenue recorded in Q3 2021 was $4.8 million. The revenue decreased over the period of year by $0.4 million or 7%.

    Net Loss

    Net loss in Q3 2021 was $0.3 million compared to $0.6 million in the same period of 2020. The net loss declined by 41% over the year.

    Conclusion

    CREX Stock outperformed by 17% from the past month. The current early trading increase in stock price is the likely consequence of its multi-million-dollar retail project with a leading company. The financial experts are praising the company for its strong investor-centric policies.

  • Here’s why Anavex Life Sciences Corp. (AVXL) Stock Sinking in Early Trading

    Here’s why Anavex Life Sciences Corp. (AVXL) Stock Sinking in Early Trading

    Anavex Life Sciences Corp. (AVXL) is a leading biotherapeutics company engaged in the development of therapeutics for neurodegenerative and neurodevelopmental disorders. The pipeline candidate ANAVEX 2-73 is used in Alzheimer’s and Parkinson’s disease along with dementia and Rett syndrome. ANAVEX 3-71 is used in Alzheimer’s treatment along with mitochondrial dysfunction and neuroinflammation.

    The price of AVXL stock during the regular trading on February 1, 2022, was last checked to be $10.75 with a 17.81% decline.

    AVXL: Events and Happenings

    On February 01, 2022, AVXL announced hopeful top-line outcomes in Phase 3 trials of ANAVEX 2-73 for treating Rett syndrome. The company also established a statistical development for the primary and secondary efficacy endpoint.

    AVXL: CEO Comments

    Speaking at the momentous occasion, the company’s CEO Christopher U Missling stated that the Phase 3 trials of ANAVEX®2-73 build on its potential to validate the meaningful developments in disease. He further added that the company is looking forward to continuing its successful journey.

    On January 10, 2022, AVXL reported optimistic top-line outcomes from ANAVEX 3-71 Phase 1 clinical trial. The trials were performed for the Frontotemporal Dementia disorder.

    On January 05, 2022, AVXL announced that the Executives presented at the H.C. Wainwright Virtual BioConnect 2022 Conference on January 10-13, 2022. On December 14, 2021, AVXL reported that the company’s management participated at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022. On November 29, 2021, AVXL announced that the company’s Executives participated at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021.

    AVXL: Key Financials

    On November 24, 2021, AVXL reported its financial results for the fiscal year ended September 30, 2021. Some of the key highlights are as follows.

    Assets

    Total assets of the company in fiscal 2021 were recorded to be $161.6 million.

    Net Loss per Share

    Basic and diluted net loss per share in fiscal 2021 was $37.9 million, or $0.54 compared with $26.3 million or $0.45 in the same period of 2020.

    AVXL announced on November 10, 2021, about the company’s management participation at the Lausanne VIII Workshop on November 17, 2021.

    Conclusion

    AVXL stock performance was not good during the last month as it dipped by 26%. The current decline in early trading is likely attributed to the recently issued positive primary and secondary endpoints outcomes. The financial experts are hoping that the company’s stock will bounce back to good shape in a shorter duration of time.

  • MediciNova, Inc. (MNOV) Stock Gaining Momentum in Premarket. Here’s why.

    MediciNova, Inc. (MNOV) Stock Gaining Momentum in Premarket. Here’s why.

    MediciNova, Inc. (MNOV) is an innovative biotherapeutics company engaged in the development of therapies for fibrotic, inflammatory, and neurodegenerative disorders. The product candidate MN-166 is studied against amyotrophic lateral sclerosis, DCM, MS, and ARDS. Another product MN-001 is assessed for IPF and NASH.

    The price of MNOV stock during the regular trading on January 31, 2022, was $2.42 with a 6.61% incline. At last check in the premarket on February 1, 2022, the stock further swelled by 6.61%.

    MNOV: Events and Happenings

    MNOV reported that it received the MN-001 patent from the Intellectual Property Office of Korea on February 01, 2022. MN-001 or tipelukast is in clinical trials for treating hyperlipoproteinemia, hypercholesterolemia, and hypertriglyceridemia.

    MNOV announced on January 31, 2022, about the receipt of allowance notification from the Intellectual Property Office of Canada. The company filed a patent application for MN-001 and MN-002 for hepatic ballooning. The company announced on January 27, 2022, about the receipt of notification from the European Patent Office regarding Intention to Grant. The company had filed a patent application for MN-166 to treat alcohol use disorder.

    On January 26, 2022, the company reported the receipt of notification from the European Patent Office for Intention to Grant of MN-001 and MN-002. On December 13, 2021, MNOV reported the receipt of allowance notification from US PTO for MN-166 and riluzole for treating ALS.

    On December 10, 2021, MNOV reported that the management presented its research poster at the Virtual 32nd International Symposium on ALS/MND on December 7 – 10, 2021. The company announced on November 22, 2021, that the management presented at the 26th Annual Meeting of the Society for Neuro-Oncology on November 18-21, 2021.

    MNOV: Key Financials

    MNOV reported its financial results on November 12, 2021, for three months ended September 30, 2021. Some of the key points are as follows.

    Revenue and Assets

    Revenue in Q3 2021 was recorded to be $0.037 million. Total current assets of the company in Q3 2021 were recorded to be $76.1 million.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $3.5 million or $0.07 compared to $3.7 million or $0.08 for the same period of 2020.

    Conclusion

    MNOV stock dipped 34% from the past few months due to the impact of pandemics on industrial development. The analysts are associating the current premarket stock incline with its new patent covering in Korea. The company is on the fast track to introduce its product line globally, which will attract more investments in the future.

  • ION Geophysical Corp. (IO) Stock Surging in Premarket, Despite any Clear Reason.

    ION Geophysical Corp. (IO) Stock Surging in Premarket, Despite any Clear Reason.

    ION Geophysical Corp. (IO) is a leading company focused on the delivery of data-driven choice-making to businesses related to offshore energy and maritime tasks. The company enables its customers to improve their investments by accessing the peculiar analytics and software.

    The price of IO stock during the regular trading on January 31, 2022, with a 3.02% incline was $0.46. At last check in the premarket on February 1, 2022, the stock further jumped by 4.91%.

    IO: Events and Happenings

    IO reported about its webinar regarding the crucial topic ‘The Digital Software Interfaces for Seismic Survey Optimization and Remote QC’ on February 2, 2022. On January 14, 2022, IO reported about its entry into a Forbearance and 5th Amendment under its Security and Credit Contract with PNC Bank, National Association. PNC agreed upon the waiver of a cross-default. Additionally, IO also reported about its entry into a contract with its 2025 Noteholders to refrain from imposing their rights till February 15, 2022.

    On December 23, 2021, IO reported the receipt of notification from the NYSE regarding non-compliance with its listing standards. The company was listed below criteria because its market capitalization was not more than $50 million over a 30-day period.

    On December 17, 2021, IO reported about the award of an agreement with a Middle Eastern Exploration and Production company. Additionally, the company also grabbed a Letter of Intent from the East African Ministry of Ports & Maritime Transport for the company’s Marlin digital infrastructure.

    IO: Key Financials

    On November 3, 2021, IO reported its financial results for the third quarter ended September 30, 2021. Some of the key features are as follows.

    Revenue

    Revenue in Q3 2021 was $44.4 million compared to $16.2 million in the same period of 2020. The company recorded a 173% increase in revenue over the period of the year.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $0.5 million or $0.02 compared to $16.6 million or $1.16 in the same period in 2020.

    Assets

    The total current assets of the company in Q3 2021 were reported to be $74 million.

    On October 14, 2021, IO reported about the inclusion of its Marlin SmartPort in Gateways to Growth which is the UK’s pioneer Ports Association program.

    Conclusion

    IO stock down-performed in the last few months by 67% due to economic recession as a result of the pandemic. The current premarket surge in the stock is likely the outcome of the company’s announcement of hosting a webinar on digital software interfaces. The financial experts believe that the company is on the right track to develop strong investor relations.

  • Air Industries Group (AIRI) Stock Steadily Moving Forward in the Aftermarket, Here’s the Reason.

    Air Industries Group (AIRI) Stock Steadily Moving Forward in the Aftermarket, Here’s the Reason.

    Air Industries Group (AIRI) is a leading developer, manufacturer, and supplier of structural components related to primary defense mechanisms. The company also develops and designs the mechanisms important for performance and safety of flights.

    The price of AIRI stock during the regular trading on January 31, 2022 with 2.35% incline was $0.84. At last check in the aftermarket, the stock was further up by 1.26%.

    AIRI: Events and Happenings

    On January 31, 2022, AIRI reported the receipt of award of a contract by its subsidiary for the production of landing gear parts for B1-B in US Air Force. The company is anticipated to earn $1.9 million from the contract by 2023.

    AIRI: CEO Comments

    Speaking at the occasion, CEO of AIRI Lou Melluzzo stated that the award of the order from a long-term customer for aircraft portfolio is a moment of pride for the company. He further added that the company is planning the expansion of its product line in 2022.

    On January 19, 2022, AIRI reported about the receipt of two contracts to develop flight-critical components of the Blackhawk helicopter. The contract was awarded to the company’s subsidiary and comes under the category of Long-Term Agreements. The company is anticipated to earn a hefty $18.2 million in five years.

    On January 6, 2022, AIRI reported about the receipt of contract by its subsidiary to manufacture and deliver the Turbine Exhaust Case parts for the PW-4000 jet engine. The contract comes under the category of Long-Term Agreement’s Life of the Program Extension. The company is expected to generate revenue of approximately $6 million over the period.

    On November 29, 2021, AIRI reported about the expansion of size and maturity of its Term Loan and Revolving Credit Facility by the Sterling National Bank. The RCF surged by $4 million or 25% from its recent limit.

    AIRI: Key Financials

    On November 3, 2021, AIRI reported its financial results for three months ended September 30, 2021. Some of the key updates are as follows.

    Net Sales

    Consolidated net sales in Q3 2021 were $14.4 million compared to $13.7 million in the same period of 2020.

    Operating Income/Loss

    Operating income in Q3 2021 was $0.17 million compared to operating loss of $0.24 million in the same period in 2020.

    Conclusion

    AIRI stock down performed 11% from the past month due to the economic restrictions put by the pandemic. The company’s stock was up in the recent aftermarket due to receipt of order from US Air Force. The analysts are optimistic that the company has preserved its reputation in the governmental offices. The current strategic collaboration will support the company’s stock in the coming days by attracting more investment options.

  • Aspira Women’s Health Inc. (AWH) Stock Shining in Aftermarket, Here’s the Reason.

    Aspira Women’s Health Inc. (AWH) Stock Shining in Aftermarket, Here’s the Reason.

    Aspira Women’s Health Inc. (AWH) is actively engaged in the development and marketing of novel bio testing solutions and analysis options to improve women’s gynecologic health-related products. The company is involved in product development for detecting ovarian cancers, endometriosis, and pelvic diseases. The lead products of the company include OVA1 and OVERA, used in detecting ovarian malignancy risk. GenetiX detects comprehensive and targeted genetic testing options with the main focus on gynecology.

    The price of AWP stock during the regular trading on January 31, 2022, was $1.21 with a sharp increase of 12.04%. At last check in the aftermarket, the stock further rocketed by 27.2%.

    AWH: Events and Happenings

    On January 31, 2022, AWH reported about its entry into a collaborative agreement to offer its testing services to Medicaid plan members equaling up to 465,000 covered lives in New Hampshire and Washington D.C. Thus, the company is credentialed as OVA1 testing provider to approximately 80% or 60 million lives of the Medicaid population.

    AWH: CEO Comments

    Speaking at the occasion, AWH CEO Valerie Palmieri said that this agreement steadfast the company’s pledge to guarantee equal access to the Medicaid population for its non-invasive ovarian cancer risk management technology.

    On January 28, 2022, AWH’s management was reported to present at The Virtual Winter Wonderland Best Ideas Investor Conference which will be held on February 8-11, 2022. On January 05, 2022, AWH reported about its entry into a commercial contract with Axia Women’s Health. Axia will provide the services to conduct in-house genetic testing using the exclusive Aspira Synergy Genetics portfolio. The term of the contract is five years.

    On January 05, 2022, AWH reported initial Q4 2021 operational results. Some of the highlights are as follows.

    • OVA1 volume in Q4 2021 increased to 4,750 units by a 23.4% incline over the year.
    • Ordering physicians number surged by 22.8% over the year to 3,211 in Q4 2021.

    AWH: Key Financials

    On November 10, 2021, AWH announced its financial results for the third quarter ended September 30, 2021. Some of the key features are as follows.

    Revenue

    Total revenue in Q3 2021 was $1.66 million compared to $1.23 in the same quarter of 2020, an increase of 34% was observed over the year.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $9.7 million or $0.09 compared to $4.2 million or $0.04 in the same period in 2020.

    Conclusion

    AWH stock dipped 73% in the last six months period due to the impact of the pandemic on the economy. The rocketing stock price in the current aftermarket is the result of the latest agreement to provide the testing services to Medicaid plan members. The financial experts predicted that with the current developmental speed, the company may achieve new heights in the women’s health industry.

  • Here’s why Silvergate Capital Corp. (SI) Stock Flying High in Aftermarket

    Here’s why Silvergate Capital Corp. (SI) Stock Flying High in Aftermarket

    Silvergate Capital Corp. (SI) is a key financial infrastructure solution provider for the online currency business. The company’s exchange network makes funding and lending solutions much easier for its customers. The company also offers cash management and loan services to its customers.

    The price of SI stock during the regular trading on January 31, 2022, was $107.7 with a phenomenal gain of 12.11%. At last check in aftermarket, the stock further shined by 11.27%.

    SI: Events and Happenings

    On January 31, 2022, SI reported about the acquisition of Diem Group’s technological and intellectual assets driving its blockchain-based payment network. The company enhanced its stablecoin infrastructure through this collaboration. The company purchased deployment and operations setup and infrastructure for the facilitation of cross-border remittances. Also included in the agreement are exclusive software tools to drive a regulatory-compliant stablecoin platform.

    SI: CEO Comments

    Speaking at the occasion, SI CEO Alan Lane said that the company identified a prerequisite for a stablecoin that is highly scalable to enhance money movement without blockades. He further added that the company is dedicated to the continued nurturing of its customer’s community needs.

    SI: Key Financials

    On January 18, 2022, SI reported its financial results for the three months ended December 31, 2021. Some of the main updates from the fourth quarter are as follows.

    Net Earnings

    Net earnings for Q4 2021 were $21.4 million against $9.1 million for the same quarter of 2020.

    Net Income per Share

    Diluted net income per share attributed to the company’s common shareholders for Q4 2021 was $18.4 million, or $0.66 compared to $9.1 million or $0.47 for the same period of 2020.

    SI and EJF Capital LLC co-announced about unveiling the EJF Silvergate Ventures Fund on December 16, 2021. It is a collaborative investment fund engaged in the development of digital currencies payment methodologies and specialty finance technology.

    SI announced the closure of its public offering of 3,806,895 shares at a public price of $145.00 per share on December 9, 2021. The net proceeds gained from the offering were up to $552.0 million. The company reported on November 9, 2021, that the Executives presented at Oppenheimer’s 4th Blockchain & Digital Assets Summit: The Evolution of Digital Assets held on November 18, 2021.

    Conclusion

    SI stock price outperformed by 5% from the past few months as it is in a good position to attract the potential investment. The financial experts are of the view that the recent boom in aftermarket stock price is the result of its acquisition of blockchain payment network assets from Diem. The experts are attributing this radical step to the sound policies of the company.